Across TCGA pan-cancer cohorts, DDO mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DDO data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DDO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DDO expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where DDO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.777	1.000	<.001	22	view →
HNSC	OS	Tertile	III,IV	0.987	0.747	.013	15	view →
LSCC	DFS	Tertile	II,III,IV	0.825	1.000	.014	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: DDO tumor-vs-normal RNA expression · all DDO data types